Article

Daily Medication Pearl: Brimonidine Tartrate/Timolol (Combigan)

Combigan is comprised of 2 components that reduce elevated intraocular pressure, whether or not associated with glaucoma.

Medication Pearl of the Day: Brimonidine tartrate/timolol (Combigan)

Indication: Brimonidine tartrate/timolol (Combigan) is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Insight:

  • Dosing: One drop in the affected eye(s), twice daily approximately 12 hours apart.
  • Dosage forms: Solution containing 2 mg/mL brimonidine tartrate and 5 mg/mL timolol.
  • Adverse events: Most common adverse reactions occurring in approximately 5% to 15% of patients include allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging
  • Mechanism of action: Combigan is comprised of 2 components: brimonidine tartrate and timolol. Each of these components decreases elevated intraocular pressure, whether or not associated with glaucoma.
  • Manufacturer: Allergan

Sources:

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com